China Exposure Strategy 2026: How Much Is Acceptable on Your Balance Sheet?
TL;DR / Executive Summary
The answer is not zero, but it must be a number, formally approved by the board, and reviewed at least annually. Most boards still lack a documented China risk-appetite threshold, which is the real strategic failure: not the level of exposure itself, but the governance vacuum that leaves it unmanaged. The emerging consensus from McKinsey, BCG, and Cambridge Associates argues for gradual de-risking rather than decoupling, yet that framing quietly assumes the risk is manageable at current concentrations, an assumption the tariff shock of 2025, China's rare earth freeze, and EU CBAM's definitive phase are now actively disproving. With effective US tariffs on China averaging 34.7% and China's trade surplus hitting a record $1.2 trillion in 2025, the structural incentives that made China concentration rational have permanently shifted.
- Boards that lack a formal China exposure ceiling, covering both revenue concentration and supply-chain dependency face an unquantified liability that no tariff truce can neutralize.
- China's rare earth export controls, expanded to cover 12 of 17 elements before a one-year pause in November 2025, demonstrate that Beijing retains asymmetric leverage over any supply chain that has not yet diversified critical input sourcing.
- The EU CBAM entered its definitive phase on January 1, 2026, creating a real carbon cost liability for China-sourced heavy industrial imports, the first structural repricing of China's manufacturing cost advantage in decades.
1. The Context
For three decades, China concentration was not a risk, it was a strategy. Multinationals that built deep manufacturing roots in China, or cultivated it as a primary revenue market, benefited from a combination of cost arbitrage, scale, and market access that no other geography could replicate. Between 1990 and 2019, China's real GDP grew at an average approaching 10% annually, and 82 percent of global supply chains now have a US connection materially affected by new tariffs. The share of US multinationals that identified China as a top-three investment priority stood at 77 percent in 2010; by 2022 it had already fallen to 45 percent according to McKinsey Global Institute, well before the 2025 tariff escalation reshaped the calculus entirely.
The complication arrived not as a single shock but as a cascade. In April 2025, President Trump signed executive orders ratcheting US tariffs on Chinese goods to a cumulative 145 percent, triggering Chinese retaliation at 125 percent and briefly creating what Cambridge Associates described as a mutual trade embargo. A Geneva truce in May 2025 pulled US reciprocal tariffs back to 30 percent and Chinese retaliatory tariffs to 10 percent, with a 90-day suspension extended through at least November 2025. Yet even at the reduced rate, compliance costs under the current tariff structure add an incremental 3 percent to total product costs, according to BCG. Meanwhile, China deployed its own asymmetric lever: in April 2025 it imposed a de facto freeze on rare earth exports pending a new licensing regime, with controls later expanded to cover 12 of the 17 rare earth elements before a temporary suspension in November 2025.
The resolution path is not the return of a stable bilateral trade regime; it is the structural redesign of corporate China exposure frameworks. China's trade surplus reached a record $1.2 trillion in 2025, and the January–February 2026 period alone produced a $213.6 billion surplus, with China pivoting exports toward ASEAN (+29.4%) and the EU (+27.8%) to replace US-bound volume. The structural shift implies that China is not decoupling from global trade, it is redirecting it, creating a bifurcated world where the risk calculus for Western multinationals depends entirely on which side of the exposure ledger they occupy. Boards that treat the Geneva truce as a resolution rather than a pause are mispricing a structural transition that will define capital allocation for the decade.
2. The Evidence
The financial footprint of China exposure has never been more legible or more punishing for concentrated bets. Nike's Greater China segment, representing approximately 15 percent of global annual sales, recorded its seventh consecutive quarter of decline in fiscal Q3 2026, with management warning of a 20 percent sales decline in Greater China for the current quarter. Shares fell to a nine-year low, a direct capital markets verdict on revenue concentration risk. Lam Research, with China representing 43 percent of revenue in fiscal Q1 2026, projected its China share would fall below 30 percent due to new US export restrictions, with an estimated $200 million sales decline across the year. Apple's experience illustrates the other side: a 38 percent surge in China revenue in the December 2025 quarter demonstrated that selective, technology-led exposure to Chinese consumers can still generate exceptional returns, but that same market simultaneously faces antitrust scrutiny, supply chain constraints, and rising competition from Huawei and Xiaomi.
On the supply chain side, the ITIF's February 2026 report found that internal value chains remain deeply dependent on China even for multinationals implementing China+1 strategies, because the PRC actively manages supply chain stickiness by encouraging deeper integration of foreign firms into its industrial ecosystem. The most common diversification destinations, Vietnam (now facing 46% US tariffs), India, Indonesia, Thailand, and Mexico, each carry their own concentration risks. BCG's January 2026 trade outlook projected China's trade growing at a 5.5% CAGR with BRICS+ nations over the next decade, reinforcing that China's global commercial footprint is expanding even as its US-bilateral relationship contracts. For boards, this bifurcation demands a split-lens framework: revenue exposure (how much of our top line is China-denominated?) must be evaluated separately from supply chain dependency (how many tiers of our inputs are China-originating?).
| Metric | Value | Source |
|---|---|---|
| US effective tariff rate on China (Nov 2025) | 34.7% average effective rate | Wharton Budget Model, Feb 2026 |
| China trade surplus, full year 2025 | Record $1.2 trillion | US-China Economic and Security Review Commission, Feb 2026 |
| IMF estimate: cost of severe trade fragmentation | Up to 7% of global GDP (~$7.4T); up to 12% with tech decoupling added | IMF, Aug 2023 |
| US-China capital market decoupling: potential economic impact | ~$2.5 trillion (Goldman Sachs: $800B Chinese stocks on US exchanges + $1.3T China's US Treasury holdings) | IndexBox / Goldman Sachs, Apr 2025 |
| China share of global rare earth mining / processing | ~60–70% of mining; >90% of processing capacity | Freshfields, Jul 2025 |
| Nike Greater China, fiscal Q3 2026 | $1.62B, down 7% YoY; 7th consecutive decline; 20% further drop forecasted Q4 2026 | Reuters, Mar 2026 |
| BCG: tariff compliance cost added to product costs | ~3% incremental cost on total product costs under current tariff structure | BCG, Feb 2026 |
| EU CBAM: Chinese steel/aluminum annual compliance cost gap | RMB 2–2.8 billion annually in early phase; expanding with 180 downstream products by 2028 | China Briefing, Mar 2026 |
| China NEV exports growth, 2025 | +50% YoY to $66.9B, China's manufacturing upgrade accelerating into higher-value sectors | USCC China Bulletin, Feb 2026 |
3. MD-Konsult Research View
The consensus position, articulated most prominently by McKinsey (in its China Imperative framework) and echoed by BCG and Cambridge Associates, holds that outright decoupling is neither feasible nor desirable, and that the correct posture is "maintaining access to China's upsides while managing increasingly complex risks." McKinsey's Greater China chairman reiterated at Davos 2026 that China "is no longer just a massive sales market; it is now an innovation base for MNCs", framing continued deep engagement as competitively necessary.
MD-Konsult's contrarian position: The strategic failure is not the level of China exposure but the absence of a formal, board-ratified China risk-appetite threshold, most multinationals have de-risking activity without de-risking governance, leaving them tactically busy but strategically unanchored.
Two data points support this position. First, ITIF's February 2026 report found that even firms actively implementing China+1 strategies retain deep supply chain dependency on China because the PRC treats outbound diversification as a supply chain security risk and actively manages integration stickiness, meaning tactical diversification without a formal exposure ceiling simply redistributes risk rather than reducing it. Second, China's April 2025 rare earth freeze and the subsequent doubling or tripling of dysprosium and terbium prices outside China demonstrates that Beijing retains a proven toolkit of asymmetric leverage that can be deployed faster than any supply chain can be restructured, meaning the risk horizon is measured in weeks, not quarters.
The strategic implication of moving early is significant. Organizations that define their China exposure ceiling before the next escalation cycle are able to allocate restructuring costs as planned capital expenditure rather than crisis-driven working capital. Companies that survived the 2025 tariff shock with manageable impact, primarily those with pre-existing supplier redundancy and documented China dependency maps, entered dual-sourcing negotiations from a position of leverage rather than dependency. That asymmetry compounds: the firm that codifies China risk governance in 2026 writes the industry standard playbook that its peers scramble to replicate in 2028.
4. Practitioner Perspective
— Chief Procurement Officer, Global Industrial Equipment Manufacturer
This observation aligns with the structural finding of the ITIF's February 2026 analysis of internal value chains, which documented that multinationals pursuing China+1 strategies frequently discover that alternative-country suppliers are themselves dependent on Chinese intermediate inputs. The concept of a multi-tier China Dependency Score, tracking not just direct China procurement but embedded Chinese content at tier-2 and tier-3 levels, is emerging as the operational standard for boards that want defensible risk governance rather than headline-level diversification metrics.
5. Strategic Implications by Stakeholder
| Stakeholder | What to Do Now | Risk to Manage |
|---|---|---|
| CTO / CIO | Commission a multi-tier China dependency audit covering tier-1 through tier-3 suppliers; flag all inputs touching Chinese rare earth processing or semiconductor supply chains. Map technology licensing agreements with Chinese entities for extraterritorial export control exposure under China's October 2025 expanded controls. | Hidden Chinese content in alternative-country suppliers; BIS compliance gaps for AI chip procurement; extraterritorial reach of China's rare earth export controls on products manufactured using Chinese technologies abroad. |
| COO / Operations | Implement a China Dependency Score (CDS) as a standing operational KPI, a weighted index of direct procurement, embedded tier-2/3 content, and logistics routing. Qualify at least two non-China sources for every critical input category above a defined spend threshold. Ensure China+1 alternative suppliers have independently verified, non-Chinese critical mineral sourcing. | Tariff truce expiration creating a cost cliff; Vietnam and Southeast Asian alternatives now carrying elevated US tariff exposure (Vietnam at 46%); China's new export licensing processes adding 45+ day lead-time risk for rare earth inputs. |
| CFO / Board | Ratify a formal China Risk Appetite Statement covering: (1) maximum China-sourced revenue as a percentage of total revenue, (2) maximum China-embedded content as a percentage of COGS, and (3) maximum China-held assets as a percentage of total assets. Stress-test margins under EU ETS price scenarios for all China-sourced heavy industrial imports, with CBAM certificate purchases beginning February 2027. Disclose China concentration metrics in annual risk reporting with year-over-year trend data. | Capital market decoupling scenario (Goldman Sachs estimates ~$2.5T potential economic impact); EU CBAM carbon cost liability accruing in 2026 and payable in 2027; politically driven demand destruction (Nike precedent: 20% China sales decline forecasted for Q4 2026). |
6. What the Critics Get Wrong
The strongest version of the "don't overreact" argument is empirical: China's exports surged to a record $3.8 trillion in 2025 despite escalating US tariffs, its trade surplus hit an all-time high, and China met its 5% GDP growth target for the year. McKinsey's Greater China chairman observed at Davos 2026 that Chinese enterprises offer cost-performance, technical maturity, and user-friendliness that alternatives still lack. Cambridge Associates noted that neither side can afford abrupt decoupling, and that the most likely trajectory is gradual strategic de-risking focused on reducing strategic dependencies, a framing that implies the status quo is a reasonable interim position.
This argument correctly identifies that full decoupling is neither feasible nor economically rational. Where it fails is in conflating "China remains economically powerful" with "current exposure levels are governable." The April 2025 rare earth freeze caused some tier-1 automotive suppliers and OEMs to begin shutting down production lines within weeks of the freeze, not because China had decoupled, but because the licensing backlog created a de facto supply interruption. The EU CBAM, now in its definitive phase, converts carbon intensity from a reporting obligation into a priced financial liability directly tied to EU ETS market volatility, a structural cost increase that compounds annually regardless of tariff truces. The critics' error is a governance error: they correctly argue that China exposure should not be reduced to zero, but they stop short of arguing that boards must define and defend a specific number, the only way to convert a narrative about "managing complexity" into an auditable risk position.
7. Frequently Asked Questions
What China revenue concentration level should trigger board-level review in 2026?
Any China revenue share above 15% for a US-headquartered firm warrants a board-level rationale and documented risk mitigants, reviewed at minimum annually. For context, Nike's 15% Greater China share, once considered moderate, produced seven consecutive quarters of revenue decline and a forecasted 20% further drop in Q4 2026. Lam Research's 43% China revenue dependency is being forcibly reduced below 30% by export controls. The threshold is not a universal number, it depends on sector, product substitutability, and competitive dynamics, but it must be a formal board decision, not an inherited outcome of legacy strategy. Absent a board-ratified ceiling, any diversification activity remains advisory rather than binding.
How is supply chain dependency different from revenue exposure, and why does it need separate governance?
Revenue exposure measures how much of top-line income is denominated in Chinese consumer or enterprise demand, primarily a demand-side, market-access, and geopolitical sentiment risk. Supply chain dependency measures how much of the cost structure originates from China-sourced inputs across all tiers, primarily a tariff, export control, and input disruption risk. A firm can have zero China revenue and still face catastrophic supply chain exposure if its critical minerals, magnets, or intermediates are sourced from Chinese processors. The ITIF's 2026 analysis found that many firms implementing China+1 manufacturing strategies are simply relocating the assembly node while the upstream supply network remains Chinese-dominated, providing headline diversification without structural risk reduction. Both dimensions require separate board-approved ceilings and separate monitoring metrics.
What does the EU CBAM mean for companies sourcing from China in 2026?
The EU Carbon Border Adjustment Mechanism entered its definitive phase on January 1, 2026, converting a reporting obligation into an accruing financial liability. Importers of steel, aluminum, cement, fertilizers, electricity, and hydrogen from China will begin purchasing CBAM certificates from February 2027, priced at EU ETS auction levels. Because China's domestic carbon price sits far below EU ETS levels, Chinese exporters cannot offset the full certificate cost, analysts estimate the annual compliance gap for Chinese steel and aluminum exporters at RMB 2–2.8 billion in the early phase, expanding as CBAM covers 180 downstream products by 2028. Finance teams should stress-test procurement margins against a range of EU ETS price scenarios now, before certificate purchases are due.
Is a China+1 strategy sufficient to manage supply chain risk?
China+1 is necessary but not sufficient. The strategy adds geographic diversity at the assembly or tier-1 manufacturing level, but it does not automatically address embedded Chinese content in tier-2 and tier-3 suppliers. ITIF documents that the PRC actively manages "supply chain stickiness" by encouraging multinationals to deepen integration while making surface-level diversification viable. Vietnam, the most popular China+1 destination for electronics and textiles, now faces US tariffs of 46%, reducing its cost advantage materially. A robust strategy requires a China Dependency Score that tracks embedded Chinese content across multiple tiers, not just the nationality of the direct supplier. Prioritization frameworks that weigh input criticality, substitutability, and tariff exposure can help operations teams rank which categories require immediate alternative qualification.
What is the regulatory risk horizon for US export controls on China?
Structurally expansionary on both sides, unlikely to reverse under any truce. The US BIS issued new semiconductor manufacturing equipment controls in December 2024, then revised its AI chip licensing policy in January 2026, shifting select advanced chips from blanket denial to case-by-case review, signaling a more calibrated but not less restrictive posture. China's October 2025 expansion of rare earth controls to 12 elements, including extraterritorial jurisdiction over products manufactured with Chinese technologies abroad, creates a legal compliance requirement that persists during the one-year suspension. Treat the November 2025 pause as operational breathing room, not policy stability, and use it to build export control compliance infrastructure that is agnostic to any specific truce status.
How should China risk be presented in board reporting?
Board-ready China risk reporting should include four components: (1) a China Revenue Concentration ratio trended over at least eight quarters; (2) a multi-tier China Supply Chain Dependency Index weighted by spend, criticality, and substitutability; (3) a Regulatory Exposure Map covering active US export controls, Chinese export control obligations, and EU CBAM liabilities; and (4) a China Risk Appetite Statement ratified by the board, specifying maximum acceptable levels for each component with a named review cadence. The business model stress-testing discipline boards apply to financial leverage should be applied with equal rigor to geopolitical concentration. Without a formal appetite statement, de-risking activity remains tactical, and tactically busy organizations are not the same as strategically protected ones.
8. Related MD-Konsult Reading
- How to Prioritize Requirements Using the MoSCoW Method, practical framework for ranking supply chain alternatives by criticality and replaceability
- What Is a Business Model and How to Write One, includes stress-testing your value chain against external supply shocks
- What Is a Business Plan and How to Write It, covers risk section governance and board-level disclosure standards
- Business Model Canvas Primer, use Key Resources and Key Partnerships blocks to map China dependency visually for board presentations
- Why Toxic Leaders Are Rewarded, and the organizational behavior patterns that allow strategic blind spots like unexamined China exposure to persist
